Active substance
Oxcarbazepine
- SFDA 11
- US FDA 35
- Health Canada 9
- US price lines 11
- NHS prices 4
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CARPAZIO 150 MG FILM COATED TABLET | 150 mg | Film-coated tablet · Oral use | 50 Blister | SAR 31.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CARPAZIO 300 MG FILM COATED TABLET | 300 mg | Film-coated tablet · Oral use | 50 Blister | SAR 45.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| CARPAZIO 600 MG FILM COATED TABLET | 600 mg | Film-coated tablet · Oral use | 50 Blister | SAR 74.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| TRILEPTAL 300MG F.C TAB | 300 mg | Film-coated tablet · Oral use | 50 Blister | SAR 46.30 | NCE · Prescription | NOVARTIS PHARMA AG | Valid |
| TRILEPTAL 600MG F.C TAB | 600 mg | Film-coated tablet · Oral use | 50 Blister | SAR 84.85 | NCE · Prescription | NOVARTIS PHARMA AG | Valid |
| TRILEPTAL 60MG\ML SUSPENTION | 60 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 123.80 | NCE · Prescription | NOVARTIS PHARMA AG | Valid |
| TRILEPTAL 150MG F.C TAB | 150 mg | Film-coated tablet · Oral use | 50 Blister | SAR 35.85 | NCE · Prescription | NOVARTIS PHARMA AG | Withdrawn by MAH · Not Marketed |
| TRILEPTAL 150MG F.C TAB | 150 mg | Film-coated tablet · Oral use | 50 Blister | SAR 48.35 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| TRILEPTAL 300MG F.C TAB | 300 mg | Film-coated tablet · Oral use | 50 Blister | SAR 69.85 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| TRILEPTAL 600MG F.C TAB | 600 mg | Film-coated tablet · Oral use | 50 Blister | SAR 114.60 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| TRILEPTAL 60MG\ML SUSPENTION | 60 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 112.55 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BENIGN EPILEPSY WITH CENTROTEMPORAL SPIKES, PANAYIOTOPOULOS SYNDROME OR LATE-ONSET CHILDHOOD OCCIPITAL EPILEPSY (GASTAUT TYPE); TRIGEMINAL NEURALGIA
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| TRILEPTAL | 150MG; 300MG; 600MG | tablet · oral | NOVARTIS | Prescription | 14 Jan 2000 |
| TRILEPTAL | 300MG/5ML | suspension · oral | NOVARTIS | Prescription | 25 May 2001 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | SUN PHARM INDS | Prescription | 9 Oct 2007 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | GLENMARK PHARMS LTD | Prescription | 9 Oct 2007 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | TARO | Prescription | 15 Nov 2007 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | ANI PHARMS | Prescription | 11 Dec 2007 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | BRECKENRIDGE PHARM | Prescription | 11 Jan 2008 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | RUBICON RESEARCH | Prescription | 9 Apr 2008 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | SUN PHARM INDS LTD | Prescription | 26 Jun 2009 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | AMNEAL PHARMS | Prescription | 17 Sep 2012 |
| OXTELLAR XR | 150MG; 300MG; 600MG | tablet, extended release · oral | SUPERNUS PHARMS | Prescription | 19 Oct 2012 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | CHARTWELL RX | Prescription | 21 Jun 2021 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | ANNORA PHARMA | Prescription | 11 Jan 2022 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | RUBICON RESEARCH | Prescription | 30 Aug 2022 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | BIONPHARMA | Prescription | 4 Nov 2022 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | AUCTA | Prescription | 30 Nov 2022 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet, extended release · oral | APOTEX | Prescription | 13 Jul 2023 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | HETERO LABS LTD III | Prescription | 20 Oct 2023 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | KANCHAN HLTHCARE | Prescription | 14 Feb 2024 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet, extended release · oral | AJANTA PHARMA LTD | Prescription | 22 Feb 2024 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | BIOCON PHARMA | Prescription | 1 Mar 2024 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet · oral | RUBICON RESEARCH | Prescription | 5 Mar 2024 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | ALKEM LABS LTD | Prescription | 18 Mar 2024 |
| OXCARBAZEPINE | 150MG; 300MG; 600MG | tablet, extended release · oral | RICONPHARMA LLC | Prescription | 22 Nov 2024 |
| OXCARBAZEPINE | 300MG/5ML | suspension · oral | MACLEODS PHARMS | Prescription | 11 Jul 2025 |
10 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-OXCARBAZEPINE | 02284294 | 150 MG | TABLET · ORAL | APOTEX INC |
| APO-OXCARBAZEPINE | 02284308 | 300 MG | TABLET · ORAL | APOTEX INC |
| APO-OXCARBAZEPINE | 02284316 | 600 MG | TABLET · ORAL | APOTEX INC |
| JAMP OXCARBAZEPINE | 02560593 | 150 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP OXCARBAZEPINE | 02560607 | 300 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP OXCARBAZEPINE | 02560615 | 600 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| TRILEPTAL 300 MG | 02242068 | 300 MG | TABLET · ORAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| TRILEPTAL 600 MG | 02242069 | 600 MG | TABLET · ORAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| TRILEPTAL ORAL SUSPENSION | 02244673 | 60 MG / ML | SUSPENSION · ORAL | NOVARTIS PHARMACEUTICALS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | OXCARBAZEPINE 150 MG TABLET | $0.10623 | per EA | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE 300 MG TABLET | $0.16669 | per EA | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE 300 MG/5 ML SUSP | $0.11023 | per ML | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE 600 MG TABLET | $0.31696 | per EA | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE ER 150 MG TABLET | $3.49768 | per EA | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE ER 300 MG TABLET | $4.73052 | per EA | 23 Sep 2026 |
| US NADAC | OXCARBAZEPINE ER 600 MG TABLET | $9.5783 | per EA | 23 Sep 2026 |
| US NADAC | TRILEPTAL 150 MG TABLET | $5.72156 | per EA | 7 Jan 2026 |
| US NADAC | TRILEPTAL 300 MG TABLET | $10.45435 | per EA | 23 Sep 2026 |
| US NADAC | TRILEPTAL 300 MG/5 ML SUSP | $1.93077 | per ML | 23 Sep 2026 |
| US NADAC | TRILEPTAL 600 MG TABLET | $19.33273 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Oxcarbazepine 150mg tablets | £22.05 | 50 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxcarbazepine 300mg tablets | £6.23 | 50 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxcarbazepine 600mg tablets | £35.79 | 50 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Oxcarbazepine 60mg/ml oral suspension sugar free | £48.96 | 250 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 23 Sep 2025 TRILEPTAL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Sep 2025 TRILEPTAL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 13 Dec 2018 OXTELLAR XR — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.